Bristol Myers Squibb completed the acquisition of RayzeBio for $4.1bn.

Bristol Myers Squibb, a global biopharmaceutical company, completed the acquisition of RayzeBio, a clinical-stage radiopharmaceutical therapeutics company, for $4.1bn. “This transaction enhances our increasingly diversified oncology portfolio by bringing a differentiated platform and pipeline, and further strengthens our growth opportunities in the back half of the decade and beyond. Radiopharmaceutical therapeutics are already transforming cancer care, and RayzeBio is at the forefront of pioneering the application of this novel modality. We look forward to supporting and accelerating RayzeBio’s preclinical and clinical programs and advancing its highly innovative radiopharmaceutical platform,” Christopher Boerner, Bristol Myers Squibb CEO.